Therapeutic cancer vaccine platform is customizable

B cells are primarily known for their robust adaptive immune response through antibody production; however, they are often overlooked among the body’s professional antigen-presenting cell (APC) populations. The Ohio State University’s Drug Development Institute (DDI) is developing a B-cell based immunotherapy platform for delivering tumor antigens that lead to a cytotoxic T cell response against tumor cells. The platform applies a proprietary ex vivo B cell activation and expansion technology without genetic manipulation resulting in a therapeutic vaccine product for either autologous or allogeneic transplant. The DDI will report in vitro results in various species, including human B cells, and in vivo studies in multiple mouse tumor models.